24 unknown. 24 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 24 | Unknown 24 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma NKG2D Chimeric Antigen Receptor NK Cell Injection - Multiple Myeloma | Early Phase 1 | Unknown | Changzhou No.2 People's Hospital | 9 | 2024-04-18 | 2024-04-23 |
| the Safety and Efficacy of SENL103 Autologous T Cell Injection SENL103 - Multiple Myeloma | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2023-08-21 | 2023-10-05 |
| Study of FasT CAR-T GC012F Injection NDMM Patients GC012F injection - Multiple Myeloma | Early Phase 1 | Unknown | Shanghai Changzheng Hospital | 18 | 2023-05-04 | 2024-02-13 |
| Clinical Study of the Safety and Efficacy of BCMA CAR-NK Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) - Immunotherapy, Multiple Myeloma | Early Phase 1 | Unknown | Shenzhen Pregene Biopharma Co., Ltd. | 19 | 2022-11-13 | 2022-12-15 |
| A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma BCMA Targeted CAR T-cells - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Early Phase 1 | Unknown | Zhejiang University | 100 | 2022-06-20 | 2022-06-24 |
| 89Zr-labeled NY008 PET Imaging in Patients 89Zr-NY008 - Multiple Myeloma | Early Phase 1 | Unknown | Affiliated Hospital of Jiangnan University | 10 | 2022-05-25 | 2022-12-19 |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma GC012F injection - Multiple Myeloma | Early Phase 1 | Unknown | Shanghai Changzheng Hospital | 15 | 2021-12-01 | 2021-09-22 |
| Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan - Multiple Myeloma, Refractory | Early Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 27 | 2021-10-01 | 2021-11-23 |
| 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma 68Ga-Pentixather, 68Ga-Pentixafor - Multiple Myeloma | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2021-08-11 | 2022-05-06 |
| A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma GPRC5D-CAR-T - Multiple Myeloma | Early Phase 1 | Unknown | Zhejiang University | 15 | 2021-06-08 | 2022-11-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma IM21 CAR-T cells - Multiple Myeloma | Early Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 10 | 2021-05-06 | 2022-07-28 |
| Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma anti-BCMA CAR-T - Multiple Myeloma | Early Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 16 | 2020-11-17 | 2020-11-19 |
| A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM BCMA/CD19 dual-target CAR-T cell immunotherapy - Multiple Myeloma | Early Phase 1 | Unknown | Hebei Yanda Ludaopei Hospital | 18 | 2020-06-01 | 2020-06-02 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma BCMA CAR-T, Fludarabine, Cyclophosphamide - Relapsed or Refractory Multiple Myeloma | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 50 | 2020-04-01 | 2020-11-13 |
| BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma GC012F injection - Multiple Myeloma | Early Phase 1 | Unknown | Shanghai Changzheng Hospital | 15 | 2020-01-16 | 2021-06-15 |
| A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma BCMA/CD19 Dual-Target CAR-T - Multiple Myeloma | Early Phase 1 | Unknown | Xijing Hospital | 18 | 2019-10-15 | 2019-12-02 |
| Treatment of Hematological Malignancy With Novel CAR-T Cells. Novel CAR-T - B-cell Non Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Unknown | Timmune Biotech Inc. | 9 | 2019-09-01 | 2019-12-10 |
| BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide - Multiple Myeloma | Early Phase 1 | Unknown | Hrain Biotechnology Co., Ltd. | 10 | 2019-07-08 | 2021-08-31 |
| Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma 68Ga-Pentixafor - Multiple Myeloma, Lymphoma | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2019-06-01 | 2019-12-27 |
| Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma BCMA-CART cells - Multiple Myeloma | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2019-03-08 | 2019-12-04 |
Showing 20 of 24. Sign in to see all of them.
Multiple Myeloma (24) · Recurrence (3) · Fasting (2) · Burkitt Lymphoma (1) · Lymphoma (1) · Lymphoma, B-Cell (1)
Blood Protein Disorders (24) · Cardiovascular Diseases (24) · Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Hemorrhagic Disorders (24) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Lymphoproliferative Disorders (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Neoplasms, Plasma Cell (24) · Paraproteinemias (24) · Vascular Diseases (24) · Disease Attributes (3)
Cyclophosphamide (3) · fludarabine (3) · 68Ga-pentixafor (2) · Bortezomib (1) · Cholestanetriol 26-Monooxygenase (1) · Dexamethasone (1) · Immune Checkpoint Inhibitors (1) · Influenza Vaccines (1) · Melphalan (1)
Shanghai Changzheng Hospital (3) · Hebei Senlang Biotechnology Inc., Ltd. (2) · Peking Union Medical College Hospital (2) · Xinqiao Hospital of Chongqing (2) · Zhejiang University (2) · Affiliated Hospital of Jiangnan University (1) · Allife Medical Science and Technology Co., Ltd. (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Changzhou No.2 People's Hospital (1) · Hebei Yanda Ludaopei Hospital (1) · Henrik Gregersen (1) · Hrain Biotechnology Co., Ltd. (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1) · Shenzhen Pregene Biopharma Co., Ltd. (1) · The Pregene (ShenZhen) Biotechnology Company, Ltd. (1)
China (22) · Denmark (1)
Chunrui Li (1) · Fang Li, M.D. (1) · Fang Liu, MD, PhD (1) · Henrik Gregersen, MD, PhD (1) · Hongyu Zhang, MD, PhD (1) · Huang He (1) · Jianmin Luo, PhD&MD (1) · Juan Du, MD (1) · Liming Tang, doctor (1) · Ming Zhou (1) · Peihua Lu, PhD&MD (1) · Qiao Yang, MD. (1) · Xi Zhang (1) · Xiaojing Yan, M.D. (1) · Xiequn Chen, Doctor (1)
PMID 37192741, PMID 31776631, PMID 36725117, PMID 39501801, PMID 40540129, PMID 41925575